ReviewActa stomatologica Croatica2025
Impaired Gustation in Liver Diseases: A Comprehensive Narrative Literature Review.
Review in Acta stomatologica Croatica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Knowledge, Attitudes, and Practice of Clinicians Regarding Dysgeusia as a Complication of (Chemo) Radiotherapy.Acta stomatologica Croatica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is one of the fastest-growing liver disorders worldwide. It is driven by obesity and type 2 diabetes. Taste perception plays a key role in appetite regulation and nutrition, also influencing other liver diseases progression. This review summarizes past and current evidence on taste disorders in liver diseases and their clinical implications. Materials and Methods: A narrative review of PubMed, Web of Science, Google Scholar, and Research Gate databases was conducted using selected MeSH terms. Results: Taste disturbances have been reported in viral hepatitis, cirrhosis, Wilson's disease, amebic liver abscesses, and NAFLD/MASLD, as well as in nutritional deficiencies (zinc, magnesium, vitamin A, branched-chain amino acids). Dysgeusia was linked to reduced appetite, sarcopenia, malnutrition, altered food preferences, and obesity risk in MASLD. Taste impairments worsen with liver dysfunction progression. Several drugs (e.g., interferon, metronidazole) contribute to dysgeusia. Zinc deficiency was the most consistent factor. Glucagon-like peptide-1 (GLP-1) receptor modulators, affecting appetite and sweet/umami perception, appear promising in MASLD therapy. Conclusions: Taste disorders are prevalent and still under-recognized in populations with liver diseases. The cause of these disorders remains unclear. Most of available studies affecting nutrients deficiencies are outdated. More research targeting molecular pathways of taste modulation (e.g., GLP-1 receptors), as well as determining the prevalence and clinical consequences of dysgeusia in specific liver disease stages is needed to better understand how micronutrient deficiencies and medications affect taste disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.